Private market
Strength in penetration, placement, promotion and supply through the right channels: pharmacies, specialized clinics, hospitals and the full distribution chain.
Company Profile
Innovation at the Service of life
Quality. Accessibility. Innovation.
Who we are
Our identity and purpose
We are a health-focused company dedicated to expanding access to high-quality medical treatments, offering a wide range of biological medicines and specialized therapies for human use. We are currently strengthening our portfolio to ensure the expansion of therapies that deliver quality and accessibility to markets across Latin America.
We incorporate therapeutic assets, monoclonal antibodies, ADCs and fertility medicines, advancing their development, health registration and commercialization in both finished products and APIs.
Our model
Strategic alliances with biotech companies, CDMOs and therapeutic asset holders, integrating scientific, regulatory, commercial and operational capabilities to bring high-specialty medicines to market with quality and accessibility.
Our vision
To build a world-class specialized pharmaceutical company at the service of life.
Public market
Extensive experience supplying government health institutions: IMSS, ISSSTE, Federal and State Health Ministries and BIRMEX, including tenders, direct awards and supply monitoring.
Medical tourism
High-complexity clinics serving international patients.
Finished product and APIs
Flexibility in the acquisition and commercialization of finished products, as well as local manufacturing from active pharmaceutical ingredient (API) supply.
Our strengths
Experience, strategy and alliance network
The combination of scientific-regulatory expertise, strategic vision and a consolidated alliance network uniquely positions us to develop and commercialize high-complexity therapies across Latin America.
7,800+
Alliance with specialized physicians and providers
Network of around 7,800 physicians and providers focused on genetic testing and diagnostics directed at precision treatments via monoclonal antibodies, a differentiating strength that no competitor can easily replicate.
Scientific expertise
Rigorous technical evaluation of biological assets, biosimilars and precision therapies.
Regulatory strategy
Extensive experience obtaining health registrations with COFEPRIS, FDA and EMA, and market access.
Distribution network
Alliances with leading private distributors and institutional channels across the country.
Medical tourism
We collaborate with clinics that attract international patients for high-complexity treatments such as ADCs and monoclonals.
Product and API
Capacity to operate in both finished products and local manufacturing with active pharmaceutical ingredients (APIs).
Allied organizations
Network of sister companies and collaborating organizations that strengthen our operational and scientific capacity.
Focus areas
Strategic therapeutic areas
01
Oncology
Monoclonal antibodies and conjugates (ADCs) for selected oncology indications: solid tumors and high-complexity targeted therapies.
- Monoclonal antibodies (mAbs)
- Antibody-drug conjugates (ADCs)
- Solid tumors
- Targeted therapies
02
Immunology
Biological assets for autoimmune and inflammatory diseases, focusing on differentiated therapies and complex biosimilars.
- Autoimmune diseases
- Inflammatory conditions
- Complex biosimilars
- Differentiated therapies
03
Fertility
Hormonal and biological medicines for assisted reproduction treatments, including FSH pen injectors and controlled ovarian stimulation therapies.
- Assisted reproduction
- Reproductive medicine
Markets
Market strategy: private, public and medical tourism
Private market
Alliances with leading distributors and pharmacy chains for access to specialized biological medicines.
- Farmacias GuadalajaraFarmacias Especializadas
- Grupo WalmartNADRO
- Farmacias San PabloMARZAM
- Farmacias Del AhorroFANASA
* Reference logos, subject to commercial agreement
Physician and provider network
~7,800
physicians and providers
Genetic testing and diagnostics directed toward precision treatments via monoclonals.
Public and institutional market
Penetration into public health organizations through tenders and institutional agreements.
- IMSS
- ISSSTE
- Health Ministry
- BIRMEX / IMSS-BIENESTAR
* Institutional reference logos
Public access strategy
- Registration in the Basic Medicines Formulary.
- Participation in IMSS, ISSSTE, BIRMEX and SSA tenders.
- Agreements with the Ministry of Health.
- Access to specialized public health programs.
International medical tourism
Working with specialized clinics that attract international patients for high-complexity treatments.
- ADCs and monoclonals
- Precision oncology treatments.
- IVF and reproduction
- In vitro fertilization cycles.
- Patient attraction
- From the USA, Latin America and Europe.
- Clinic alliances
- Network of certified clinics.
Capabilities and alliances
Internal capabilities and collaboration models
Scientific evaluation
- Technical analysis of biological assets.
- Scientific and preclinical feasibility.
Regulatory strategy
- Regulatory feasibility analysis.
- Registration with COFEPRIS, FDA and EMA.
Operational management
- Coordination with CDMOs and manufacturers.
- Quality management and traceability.
Pharmacovigilance
- NOM-220-SSA1-2016 compliant system.
- Detection and reporting of adverse events.
Commercialization
- Specialized institutional market.
- Market access strategy.
Strategic alliances
- Licensing and technology transfer.
- Development and supply agreements.
- Confidentiality
- Regulatory compliance
- Transparency
- Strategic alignment
- Long-term vision
Quality and compliance
Standards that define our operations
Quality and regulatory compliance are fundamental pillars. We operate under a framework aligned with current health legislation and international standards of quality, safety and pharmacovigilance.
Quality processes
- GMP
- Good Manufacturing Practices.
- Document management
- Quality control and documentation.
- Supplier qualification
- Rigorous evaluation and qualification.
- Risk management
- Deviation handling and risk control.
- Legal compliance
- Regulatory and contractual compliance.
Our team
Science, strategy and experience in one team
A multidisciplinary team with experience in pharmaceutical development, health regulation, life sciences, commercial strategy and allied organizations across the healthcare ecosystem.
- 01Decades of leadership in general management within the pharmaceutical industry, with strategic vision across public and private markets and proven experience in high-specialty and biotechnology therapies.
- 02Medical-scientific expertise in human reproduction, genetic diagnostics and precision biological therapies, with recognition across Latin America.
- 03Frontier research in regenerative medicine and genetic modification, with a track record at leading scientific institutions and the ability to translate complex science into concrete therapeutic solutions.
- 04Strategic pharmaceutical product management from concept to launch, integrating medical, regulatory, commercial and communication teams with a focus on reproductive health and specialized therapies.
Next steps
Let's build something together
We are open to conversations with manufacturers, CDMOs, technology partners and institutional clients looking for a serious, technical and committed pharmaceutical partner.
- 01
Collaboration proposal
Share your asset, technology or commercial interest with us.
- 02
Information request
We'll send you our portfolio and institutional information.
- 03
Technical meeting
Schedule a session with our scientific-regulatory team.
- 04
Confidentiality agreement
We start with an NDA to protect both parties.
Contact
- Website
- www.starseedpharma.com
Quality. Accessibility. Innovation.
Constant innovation at the service of life